TABLE 4.

Results of past studies of LRR among T1-T2, node-negative breast cancers treated with mastectomy without PMRT^{1, 3-6}

Study	N	% received systemic therapy	Treatment regimen	Median follow-up (yrs)	LRR rate (%)
Abi-Raad et al	1136	38.4%	Not stated	9	5.2%
Truong et al	1994	80.5%	Trastuzumab used in 53% of HER2+ patients, otherwise not stated	4.3	3.1%
Yildirim et al	502	56% chemotherapy, 43% tamoxifen	Among those who received chemotherapy, 67% had CMF	6.4	2.8%
Wallgren et al	1275	33% chemotherapy	One cycle of CMF	15.3	16%, 19%*
Sharma et al	753	Cannot be calculated	Not stated	7.5	2.1%
Mamtani et al (Current study)	657	86%	Among those who received chemotherapy, 51% had ACT; Trastuzumab used in 70% of HER2+ patients	5.6	4.7%

^*Reported as 16% among pre-menopausal patients and 19% among post-menopausal patients